Priliximab
Priliximab is a monoclonal antibody designed for the treatment of cancer. It is a type of biopharmaceutical that is developed through biotechnology processes. Priliximab is one of the many therapeutic antibodies that have been developed to target specific cells in the body, in this case, cancer cells.
History[edit | edit source]
The development of Priliximab is part of the broader history of monoclonal antibody therapy, which began in the 1970s with the discovery of the ability to create monoclonal antibodies in the laboratory. This discovery led to the development of a new class of drugs that could target specific cells in the body, opening up new possibilities for the treatment of diseases like cancer.
Mechanism of Action[edit | edit source]
Priliximab works by binding to a specific protein on the surface of cancer cells. This binding triggers a series of events that lead to the destruction of the cancer cell. The exact mechanism of action of Priliximab is still under investigation, but it is believed to involve the activation of the body's immune system to attack the cancer cells.
Clinical Trials[edit | edit source]
Priliximab has been tested in several clinical trials to evaluate its safety and efficacy in the treatment of various types of cancer. These trials are a crucial part of the drug development process, providing the evidence needed to gain regulatory approval for the use of the drug in patients.
Side Effects[edit | edit source]
Like all drugs, Priliximab can cause side effects. These can range from mild reactions, such as rash or fever, to more serious complications, such as infection or organ damage. The risk of side effects must be weighed against the potential benefits of the drug in the treatment of cancer.
Future Directions[edit | edit source]
The development of Priliximab and other monoclonal antibodies represents a significant advance in the treatment of cancer. However, much work remains to be done to fully understand the potential of these drugs and to optimize their use in patients. Future research will likely focus on improving the efficacy of Priliximab, reducing its side effects, and exploring its use in combination with other treatments.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
